Skip to content

You are here:Home arrow Health and Medical arrow Diseases and Conditions arrow Respiratory Ailments arrow COPD Medications Linked With Increased Risk of Death
COPD Medications Linked With Increased Risk of Death E-mail
Written by Administrator   

COPD InhalerThe use of inhaled anticholinergic agents (medications that help reduce bronchospasm) by patients with chronic obstructive pulmonary disease (COPD) is associated with a significantly increased risk of heart attack, stroke of cardiovascular death, according to a meta-analysis of randomized trials published in the September 24, 2008 issue of JAMA.

Inhaled anticholinergic agents (including ipratropium bromide or tiotropium bromide) are widely used in patients with chronic obstructive pulmonary disease (COPD), but their effect on the risk of cardiovascular outcomes is unknown, according to background information in the article. Inhaled tiotropium is the most widely prescribed medication for COPD, with more than 8 million patients worldwide having used it since its approval in 2002.

Sonal Singh, M.D., M.P.H., of Wake Forest University School of Medicine, Winston-Salem, N.C., and colleagues conducted a meta-analysis to determine cardiovascular risks (myocardial infarction [MI; heart attack], stroke, and cardiovascular death) associated with the long-term use of inhaled anticholinergics. After identifying and a detailed screening of 103 articles, 17 randomized trials enrolling 14,783 patients were analyzed. Follow-up duration ranged from 6 weeks to 5 years.

The analysis indicated that inhaled anticholinergics significantly increased the risk, by 58 percent, of cardiovascular death, heart attack, or stroke (1.8 percent vs. 1.2 percent for controls). Among individual components of the primary outcome, inhaled anticholinergics significantly increased the risk of heart attack by 53 percent (1.2 percent vs. 0.8 percent for controls) and also significantly increased (by 80 percent) the risk of cardiovascular death (0.9 percent vs. 0.5 percent for controls).

All-cause death was reported in 149 of the patients treated with inhaled anticholinergics (2.0 percent) and 115 of the control patients (1.6 percent). A sensitivity analysis restricted to 5 long-term trials (greater than 6 months) confirmed the significantly increased risk (73 percent) of cardiovascular death, heart attack, or stroke (2.9 percent of patients treated with anticholinergics vs. 1.8 percent of the control patients).

“Chronic obstructive pulmonary disease is an independent risk factor for cardiovascular hospitalization and cardiovascular death. Cardiovascular death is a more frequent cause of death in patients with COPD than respiratory causes, with the proportion of cardiovascular deaths increasing with the severity of the disease,” the authors write.

“Clinicians need to closely monitor patients with COPD who are taking long-term anticholinergics for the development of cardiovascular events. Clinicians and patients should carefully consider these potential long-term cardiovascular risks of inhaled anticholinergics in the treatment of COPD, and decide whether these risks are an acceptable trade-off in return for their symptomatic benefits.” (Source: JAMA. 2008;300[12]:1439-1450)

About Chronic Obstructive Pulmonary Disease (COPD) 

Chronic obstructive pulmonary disease, or COPD, refers to a group of diseases that cause airflow blockage and breathing-related problems. It includes emphysema, chronic bronchitis, and in some cases asthma. COPD is the fourth leading cause of death in America, behind heart disease, cancer and stroke.

Twelve million Americans have been diagnosed with COPD and at least another 12 million have symptoms that have not been diagnosed. Estimates of the total incidence of COPD in America range from 24 to 30 million.  COPD is projected to rank fifth in 2020 in burden of disease worldwide.

In the United States, tobacco use is a key factor in the development and progression of COPD, but asthma, exposure to air pollutants in the home and workplace, genetic factors, and respiratory infections also play a role. In the developing world, indoor air quality is thought to play a larger role in the development and progression of COPD than it does in the United States.

< Prev   Next >

 Contact Our News Editors

  • For any corrections of factual information, or to contact the editors please use our feedback form.
  • Please send any medical, health, fitness or anti-aging news press releases to: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it  
  Back to Front Page
 List of all Health and Medical Sections






A to Z Health:
Allergies | Alzheimers | Anxiety | Arthritis | Asthma | Attention Deficit Hyperactivity Disorder (ADHD) | Autism | Auto-Immune Disorders | Bird Flu | Bladder Cancer | Bone Disease | Brain Tumor Breast Cancer | Cardiovascular Disease | Cervical Cancer | Cholesterol (HDL, LDL) | Chronic Fatigue Syndrome | Cold and Flu | Colitis | Colon Cancer | Colorectal Cancer | Crohn's Disease Cystic Fibrosis | Dementia | Depression | Diabetes | Eczema | Endometrial Cancer | Erectile Dysfunction | Esophageal Cancer | Eye Disease | Fibromyalgia | Gastrointestinal Problems | Hair Loss Headaches (e.g., migraines, sinus, etc.) | Head and Neck | Hearing Loss | Heartburn | Heart Disease | Hormone Disorders | Hypertension (High Blood Pressure) | Infectious Diseases | Joint Pain Kidney Cancer | Kidney Disease | Leukemia | Liver Cancer | Liver Disease | Lung Cancer | Lung Disease | Lymphoma | Melanoma | Mesothelioma | Migraines | Multiple Sclerosis | Obesity Obessive Compulsive Disorder (OCD) | Osteoporosis | Ovarian Cancer | Pancreatic Cancer | Parkinson’s Disease | Pediatric Cancer | Prostate Cancer | Prostate Health | Psoriasis | Respiratory Ailments | Sarcoma | Skin Cancer | Skin Diseases & Conditions | Sleep Disorders | Stomach Cancer | Stress | Stroke | Testicular Cancer | Thyroid Cancer | Thyroid Disease | Urology/Renal

Visitors: 23909091
Copyright © 2007 - 2017 Muscle Mag Fitness | Muscle, Fitness and Health Resource All rights reserved. Use of this site constitutes acceptance of Muscle Mag Fitness terms of service.
Designed by: